Table 1.
Patient Characteristics
| Variable | Bu-Mel (N=104) |
Melphalan (N=98) |
|---|---|---|
| Age at auto-HCT, years (IQR) | 58.9 (53.3-65.0) | 59.5 (51.9-64.2) |
| Median age at auto-HCT, years (range) | 57.9 (31.7-70.9) | 57.6 (34.3-70.6) |
| Gender | ||
| Male | 61 (59%) | 55 (56%) |
| Cytogenetic risk | ||
| High | 32 (31%) | 30 (31%) |
| Standard | 72 (69%) | 68 (69%) |
| Specific abnormalities | ||
| Deletion 17p | 11 (11%) | 8 (8%) |
| Translocation (4; 14) | 6 (6%) | 4 (4%) |
| Amplification 1q | 19 (18%) | 20 (20%) |
| ≥ 3 abnormalities | 3 (3%) | 3 (3%) |
| R-ISS | ||
| I | 33 (39%) | 34 (47%) |
| II | 27 (32%) | 21 (29%) |
| III | 24 (29%) | 18 (25%) |
| Missing | 20 | 25 |
| Serum LDH | ||
| Normal | 63 (89%) | 59 (86%) |
| Abnormal | 8 (11%) | 10 (14%) |
| Missing | 33 | 29 |
| HCT-CI, median (range) | 2 (0-7)* | 1 (0-7) |
| 0 | 35 (35%) | 44 (45%) |
| 1-2 | 23 (23%) | 39 (40%) |
| ≥3 | 43 (43%) | 15 (15%) |
| Response to induction | ||
| sCR + CR | 12 (12%) | 15 (15%) |
| nCR | 10 (10%) | 13 (13%) |
| VGPR | 32 (31%) | 28 (29%) |
| PR | 46 (44%) | 36 (37%) |
| SD | 4 (4%) | 6 (6%) |
| Induction regimen | ||
| VRD | 62 (60%) | 56 (57%) |
| VCD | 18 (17%) | 16 (16%) |
| KRD | 9 (9%) | 15 (15%) |
| VD | 6 (6%) | 7 (7%) |
| CBAD | 3 (3%) | 2 (2%) |
| RD | 5 (5%) | 1 (1%) |
| Other | 1 (1%) | 1 (1%) |
| Maintenance regimen | ||
| Lenalidomide (Len) | 59 (57%) | 57 (58%) |
| Len+Elotuzumab | 12 (12%) | 8 (8%) |
| Len+lxazomib | 6 (6%) | 8 (8%) |
| Len+Dexamethasone | 4 (4%) | 2 (2%) |
| Bortezomib | 6 (6%) | 9 (9%) |
| None | 17 (16%) | 14 (14%) |
| Duration of maintenance therapy (months) | 16.0 (8.5-35.9) | 10.1 (3.7-22.3) |
Data are n (%) or median (IQR) unless otherwise specified.
Bu, busulfan; Mel, melphalan; Auto-HCT, autologous hematopoietic cell transplantation; R-ISS, revised international staging system; LDH, lactate dehydrogenase; HCT-CI, hematopoietic cell transplantation-comorbidity index; CR, complete response; sCR, stringent CR; nCR, near CR; VGPR, very good partial response; PR, partial response; SD, stable disease; PD, progressive disease; VRD, bortezomib-lenalidomide-dexamethasone; VCD, bortezomib-cyclophosphamide-dexamethasone; KRD, carfilzomib-lenalidomide-dexamethasone; VD, bortezomib-dexamethasone; CBAD, cyclophosphamide-bortezomib-adriamycin-dexamethasone; RD, lenalidomide-dexamethasone
*
n=101